

**In the Claims**

Please replace all prior versions, and listings, of claims in the application with the following list of claims:

1.-87. (Canceled)

88. (Previously presented) An isolated HLA DRB1\*15-binding peptide consisting of the amino acid sequence set forth as SEQ ID NO:7 with 0-10 amino acids added to either or both ends of the amino acid sequence set forth as SEQ ID NO:7, and an endosomal targeting signal comprising an endosomal targeting portion of human invariant chain Ii or LAMP-1.

89. (Previously presented) The isolated HLA DRB1\*15-binding peptide of claim 88 wherein the amino acid sequence is selected from the group consisting of SEQ ID NO:3, SEQ ID NO:4, and SEQ ID NO:7.

90. (Previously presented) The isolated HLA DRB1\*15-binding peptide of claim 88 wherein the isolated peptide is non-hydrolyzable.

91. (Currently amended) ~~An~~ The isolated non-hydrolyzable HLA DRB1\*15-binding peptide ~~of claim 90 wherein the isolated peptide is~~ selected from the group consisting of peptides comprising D-amino acids, peptides comprising a -psi[CH<sub>2</sub>NH]-reduced amide peptide bond, peptides comprising a -psi[COCH<sub>2</sub>]-ketomethylene peptide bond, peptides comprising a -psi[CH(CN)NH]-(cyanomethylene)amino peptide bond, peptides comprising a -psi[CH<sub>2</sub>CH(OH)]-hydroxyethylene peptide bond, peptides comprising a -psi[CH<sub>2</sub>O]-peptide bond, and peptides comprising a -psi[CH<sub>2</sub>S]-thiomethylene peptide bond;

wherein the amino acid sequence of the peptide consists of the amino acid sequence set forth as SEQ ID NO:7 with 0-10 amino acids added to either or both ends of the amino acid sequence set forth as SEQ ID NO:7, and an endosomal targeting signal comprising an endosomal targeting portion of human invariant chain Ii or LAMP-1.

92. (Previously presented) A composition comprising  
an isolated MAGE-A1 HLA class I-binding peptide, and  
the isolated MAGE-A1 HLA DRB1\*15-binding peptide of claim 88,  
wherein the HLA class I-binding peptide and the MAGE-A1 HLA DRB1\*15-binding  
peptide are separate isolated peptides.
93. (Previously presented) The composition of claim 92 wherein the amino acid sequence  
selected from the group consisting of SEQ ID NO:3, SEQ ID NO:4, and SEQ ID NO:7.
94. (Previously presented) The composition of claim 92 wherein the isolated peptide is  
non-hydrolyzable.
95. (Currently amended) A The composition comprising  
an isolated MAGE-A1 HLA class I-binding peptide, and  
the isolated non-hydrolyzable MAGE-A1 HLA DRB1\*15-binding peptide of claim 91,  
wherein the HLA class I-binding peptide and the non-hydrolyzable MAGE-A1 HLA  
DRB1\*15-binding peptide are separate isolated peptides of claim 94 wherein the isolated peptide  
is selected from the group consisting of peptides comprising D-amino acids, peptides comprising  
a-psi[CH<sub>2</sub>NH]-reduced amide peptide bond, peptides comprising a-psi[COCH<sub>2</sub>]-ketomethylene  
peptide bond, peptides comprising a-psi[CH(CN)NH]-(cyanomethylene)amino peptide bond,  
peptides comprising a-psi[CH<sub>2</sub>CH(OH)]-hydroxyethylene peptide bond, peptides comprising a  
-psi[CH<sub>2</sub>O]-peptide bond, and peptides comprising a-psi[CH<sub>2</sub>S]-thiomethylene peptide bond.